What changed
$NVO — AVOID 📊 | 6 MONTHS THESIS
🎯 latest | Rev $13.6B | EPS $6.63 vs $6.96 🔴
💡 Consensus expects Ozempic/Wegovy to sustain >25% revenue growth, but Q2 miss and rising competitive pressure from tirzepatide signal a structural slowdown. Market underestimates margin compression from rebates and the speed of patient churn.
📉 Reward/risk: 0.28:1
🏢 Business Quality: 8/10
📊 Valuation: cheap on trailing P/E (7.2x) vs peer band 10–32x, but justified by growth concerns.
🔮 Catalyst: No positive catalyst within 3-month horizon; recent earnings miss is the only event.
💰 Entry: $47.64, stop $42.0, target $49.23
⚖️ Avoid NVO long: earnings miss and slowing obesity momentum create a 0.3:1 reward/risk setup with only 3.7% upside to base case; wait for a re-rating catalyst or a deeper pullback before considering entry.
📊 Our read: AVOID. Full analysis →
https://stockduty.xyz/s/NVO0625